We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

NanoViricides Inc (NNVC) USD0.001

Sell:$1.47 Buy:$1.52 Change: $0.02 (1.31%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$1.47
Buy:$1.52
Change: $0.02 (1.31%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$1.47
Buy:$1.52
Change: $0.02 (1.31%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

Contact details

Address:
1 Controls Drive
SHELTON
06484
United States
Telephone:
+1 (203) 9376137
Website:
www.nanoviricides.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NNVC
ISIN:
US6300873022
Market cap:
$21.66 million
Shares in issue:
14.35 million
Sector:
Biotechnology
Exchange:
-
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Anil Diwan
    President, Chief Executive Officer, Executive Chairman of the Board
  • Meeta Vyas
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.